@FiercePharma: Eli Lilly's $15B battle for longer Alimta monopoly hits court today. Article | Follow @FiercePharma
@EricPFierce: India to consider putting handcuffs on foreign investment to protect domestic generics market. Story | Follow @EricPFierce
@CarlyHFierce: Merck stops selling Zilmax to study livestock drug's safety; the drug added $159M to sales in 2012. News | Follow @CarlyHFierce
> Nevada State Sen. Richard Segerblom has joined calls for Purdue Pharma to hand over a list of doctors suspected of recklessly prescribing its addictive painkiller OxyContin. Report
> GlaxoSmithKline ($GSK) has split its U.K. and Ireland businesses and named leadership teams for each to prepare for its planned divestment of the drink brands Lucozade and Ribena. Report
> Health Canada has approved ThromboGenics' eye drug Jetrea to treat symptomatic vitreomacular adhesion. Report
> India's Lupin is looking for branded drugs to buy in the United States. Report
> A Novartis ($NVS) executive in India scolded the country's recent intellectual property moves, saying the revocation of patents and issuance of compulsory licenses creates uncertainty and undermines R&D investment. Report
@FierceMedDev: Special report: Device-tax worries aside, major med tech mostly added jobs in 2012. Feature | Follow @FierceMedDev
@DamianFierce: How can early-phase CROs brave a tough market? We asked two of the biggest. Editor's corner | Follow @DamianFierce
@MarkHFierce: Orthofix is in trouble again, this time for not filing its financials on time. Press release | Follow @MarkHFierce
@MichaelGFierce: Last week's Chutes & Ladders roundup: Pharma veteran Jeffrey Jonas takes top spot at Sage & more in biotech/pharma hirings. More | Follow @MichaelGFierce
> Abbott closes $250M deal for eye surgery biz. Article
> St. Jude snags Endosense for up to $331M. Report
> Cigna policy change risks hammering Myriad's Dx bottom line. Story
Biotech News
@FierceBiotech: Will the biotech dealmaking lull extend through the rest of the year? More | Follow @FierceBiotech
@JohnCFierce: Novartis lashes out at India's patent rulings, says country is losing R&D. But India clearly doesn't care about R&D. More | Follow @JohnCFierce
@RyanMFierce: Pfizer's social head touted some of the internal and external feats of the pharma giant. Article | Follow @RyanMFierce
@EmilyMFierce: Inovio vaccine kills malaria, boosts immune response in animals. Story | Follow @EmilyMFierce
> GTx shares eviscerated after muscle drug flops in PhIII cancer studies. Story
> New DMD data gives Sarepta an edge in GlaxoSmithKline showdown. Article
> Analyst lays out worst-case scenario for Dendreon. Item
CRO News
> Quintiles buying Novella with eye on emerging biotechs. More
> AMRI's shares crater as partner Bristol-Myers ditches depression drug. Article
> Risk-based monitoring could be a boon to CROs. Item
> Boehringer pulls plug on VA commercial plant. Story
> Express Scripts sells CRO biz to private equity outfit. More
> WuXi ratchets up expectations after banner quarter. News
> AMRI's shares crater as partner Bristol-Myers ditches depression drug. Report
Biotech IT News
> RTI wins NIH support to advance web-based toolkit for genetics research. News
> India's InterpretOmics scores $1.6M round to fuel bioinformatics biz. Report
> Pfizer taps online marketplace for outsourcing research. Story
> FDA's former IT boss nails down industry gig. More
> Certara, provider of drug research software, buys Michigan rival. Article
And Finally... The U.S. obesity rate is growing more slowly than in years past, but "extreme" obesity has risen dramatically. Report